Drug intelligence / Profile preview

dexamethasone + diclofenac

Development stage
Phase 4
Lead developer
UZ Leuven
Modality
Small Molecules
Administration
Ophthalmic
01

Overview

dexamethasone + diclofenac (preservative-free) is a combination treatment regimen consisting of the corticosteroid dexamethasone 0.1% (as Monofree Dexamethason) and the non-steroidal anti-inflammatory drug (NSAID) diclofenac 0.1% (as Dicloabak). This preservative-free formulation is used to manage postoperative inflammation and prevent cystoid macular edema following cataract surgery, while aiming to reduce the incidence of iatrogenic dry eye disease compared to preserved alternatives. Dexamethasone functions as a glucocorticoid receptor agonist to inhibit inflammatory pathways, and diclofenac acts by inhibiting cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby reducing prostaglandin synthesis. This specific combination is the subject of a Phase 4 clinical trial conducted by Universitaire Ziekenhuizen KU Leuven.

Brand names
Monofree DexamethasonDicloabak
Other names
preservative-free dexamethasone 0.1% and diclofenac 0.1% eye dropspreservative-free drop treatment
02

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on dexamethasone + diclofenac.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dexamethasone + diclofenac.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call